ITRAQとCNVにおけるTAB1の保護効果に基づいた胆管新血管化に関するプロテオミクス
Yong Du1,2, Shaoqiu Jiang3, Lujia Feng1
1Shenzhen Eye Hospital, Shenzhen Eye Center, Southern Medical University, Futian District, 18 Zetian Road, Shenzhen, 518040, People's Republic of China.
Scientific reports
|August 23, 2025
まとめ
この研究は,TAB1タンパク質が,年齢関連の黄斑変性 (AMD) の盲目の主要な原因である冠状腺新血管化 (CNV) に保護的役割を果たしていることを明らかにしています. TAB1の過剰発現は,中枢神経線維の病変を減少させ,炎症経路に影響を与え,潜在的な治療標的として示唆しました.
科学分野:
- 眼科について
- 分子生物学
- 生物化学
背景:
- 冠状新血管化 (CNV) は,老化による黄斑変性 (AMD) の重篤な合併症であり,しばしば視力低下につながる.
- 有効な治療法を開発するには,CNVの背後にある分子メカニズムを理解することが重要です.
研究 の 目的:
- iTRAQを使用してCNVのタンパク質発現プロフィールを調査する.
- 差異的に発現するタンパク質を分析することによって,CNVの潜在的な治療標的を特定する.
- CNVの病原性におけるTAB1の機能的役割を解明する.
主な方法:
- iTRAQを用いたプロテオミクス分析で,CNVと正常なラットコロイドのタンパク質発現を比較した.
- 差異的に発現するタンパク質のバイオ情報分析 (KEGGとGOの注釈)
- ウェスタン・ブロッティングによるタンパク質発現の検証
- AAV媒介によるTAB1過剰発現を用いたインビボ試験で,中枢神経線維の病変に対する効果を評価した.
- IL-6とIL-18のレベルを測定するELISA
- NF-kB経路の活性化を分析する
主要な成果:
- 合計で4380のタンパク質が特定され,そのうち49のタンパク質が上昇調節され,241のタンパク質が低下調節された.
- TAB1の過剰発現は,体内において,CNV病変の領域を有意に減少させた.
- TAB1過剰発現は,RPE細胞増殖を増加させ,IL-6レベルを上昇させ,IL-18レベルを低下させました.
- NF- kB経路は,TAB1の観察された効果に関与していた.
結論:
- TAB1は,CNVの進行に対する保護効果を示しています.
- TAB1は主要な炎症性サイトカイン (IL-6,IL-18) とNF- kB経路に影響を与える.
- TAB1とその関連信号経路は,AMDにおけるCNVの治療に有望な治療目標です.
関連する概念動画
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...